Cytosorbents
CTSO
#9825
Rank
A$69.03 M
Marketcap
A$1.10
Share price
-1.20%
Change (1 day)
-23.77%
Change (1 year)

Revenue for Cytosorbents (CTSO)

Revenue in 2025 (TTM): A$55.76 Million

According to Cytosorbents's latest financial reports the company's current revenue (TTM ) is A$54.35 Million. In 2024 the company made a revenue of A$57.22 Million an increase over the revenue in the year 2023 that were of A$45.62 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Cytosorbents from 2009 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) A$55.76 M-2.55%
2024 A$57.22 M25.42%
2023 A$45.62 M5.75%
2022 A$43.14 M-22.01%
2021 A$55.32 M7.83%
2020 A$51.3 M57.79%
2019 A$32.51 M13.11%
2018 A$28.74 M67.72%
2017 A$17.14 M50.57%
2016 A$11.38 M104.48%
2015 A$5.56 M44.9%
2014 A$3.84 M317.05%
2013 A$0.92 M-282.91%
2012 -A$0.51 Million-1531.48%
2011 A$0.03 M
2010 N/A
2009 N/A

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Meridian Bioscience
VIVO
A$0.50 B 822.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Hologic
HOLX
A$6.08 B 11,085.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Boston Scientific
BSX
A$29.13 B 53,490.05%๐Ÿ‡บ๐Ÿ‡ธ USA